Sign in Subscribe
Apoptosis

Immunogenicity of Tislelizumab: Insights into Anti-Drug Antibody (ADA) Incidence and Validation Cut Points

Strategic Insights

— 1 min read

Researchers have made significant progress in understanding the immunogenicity of tislelizumab, a humanized anti-PD-1 antibody, which has been analyzed in a comprehensive study involving 3815 patients. The investigation focused on the incidence of anti-drug antibodies (ADAs) and the feasibility of assessing the suitability of validation cut points (VCPs) using statistical methods. The results of this study have important implications for the development and evaluation of biotherapeutics, particularly in the context of cancer treatment.

Key Takeaways:

  • The incidence of ADA in tislelizumab-treated patients was reported to be 19.2%.
  • The study demonstrated that statistical methods can effectively assess the suitability of VCPs, providing valuable insights into the evaluation of immunogenicity.
  • In-study cut points are recommended for datasets with significantly different median and variance, while VCPs may be appropriate when only medians differ.
  • Fourteen datasets exhibited significant differences from the validation dataset in both medians and variances, with FPRs exceeding the 2-11% range.
  • Seven datasets only differed significantly in medians, with five having out-of-range FPRs and their positive rates narrowly affected by cut point alteration.
  • The study's findings emphasize the importance of considering statistical methods in evaluating the immunogenicity of biotherapeutics.

Statistics:

  • 3815 patients were analyzed for ADA incidence.
  • 19.2% of patients showed ADA incidence.
  • 14 datasets exhibited significant differences from the validation dataset in both medians and variances.
  • 7 datasets only differed significantly in medians.
  • 5 datasets had out-of-range FPRs.
  • 2-11% range for FPRs.
  • The study used automated methods to assess the distribution of ADAs in validation populations.

Sources:

  • Immunogenicity of tislelizumab: clinical summary of ADA incidence and feasibility of assessing the suitability of validation cut points using statistical methods. Journal of Immunological Methods, 2025:113983.
  • Elsevier: www.elsevier.com
  • Journal of Immunological Methods: www.journals.elsevier.com/journal-of-immunological-methods/

Read more